Integrated Diagnostics (Indi; Seattle), a molecular diagnostic company that was founded in 2009 and is focused on the use of blood-based proteomic tests, said it has raised $30.25 million from the closing of its Series B and $17 million in non-dilutive debt financing provided by Life Sciences Alternative Funding. The financing round was led by Baird Capital and joined by Indi's existing investors, InterWest Partners and the Wellcome Trust.